Tino Schenk
Overview
Explore the profile of Tino Schenk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
637
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schutt J, Brinkert K, Plis A, Schenk T, Brioli A
Cancer Drug Resist
. 2024 Jul;
7:26.
PMID: 39050883
Despite significant advances in the understanding of multiple myeloma (MM) biology and the development of novel treatment strategies in the last two decades, MM is still an incurable disease. Novel...
2.
Ren S, Bai F, Schnell V, Stanko C, Ritsch M, Schenk T, et al.
Cell Rep
. 2024 Jan;
43(1):113644.
PMID: 38180837
Extensive remodeling of the female mammary epithelium during development and pregnancy has been linked to cancer susceptibility. The faithful response of mammary epithelial cells (MECs) to hormone signaling is key...
3.
Skopek R, Palusinska M, Kaczor-Keller K, Pingwara R, Papierniak-Wygladala A, Schenk T, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982453
Immortalized cell lines are widely used in vitro tools in oncology and hematology research. While these cell lines represent artificial systems and may accumulate genetic aberrations with each passage, they...
4.
Sbirkov Y, Vergov B, Dzharov V, Schenk T, Petrie K, Sarafian V
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834787
The prognosis for patients with relapsed childhood acute lymphoblastic leukaemia (cALL) remains poor. The main reason for treatment failure is drug resistance, most commonly to glucocorticoids (GCs). The molecular differences...
5.
Stengel S, Petrie K, Sbirkov Y, Stanko C, Ghazvini Zadegan F, Gil V, et al.
Br J Haematol
. 2022 Apr;
198(2):338-348.
PMID: 35468223
Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling, contribute to enhanced proliferation and the differentiation blockade of...
6.
Schutt J, Nagler T, Schenk T, Brioli A
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439223
Multiple Myeloma (MM) is a malignancy of plasma cells infiltrating the bone marrow (BM). Many studies have demonstrated the crucial involvement of bone marrow stromal cells in MM progression and...
7.
Sbirkov Y, Ivanova T, Burnusuzov H, Gercheva K, Petrie K, Schenk T, et al.
Front Oncol
. 2021 Apr;
11:632181.
PMID: 33791218
Childhood acute lymphoblastic leukaemia (cALL) accounts for about one third of all paediatric malignancies making it the most common cancer in children. Alterations in tumour cell metabolism were first described...
8.
Szymanski L, Skopek R, Palusinska M, Schenk T, Stengel S, Lewicki S, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33322246
The retinoids are a group of compounds including vitamin A and its active metabolite all-trans-retinoic acid (ATRA). Retinoids regulate a variety of physiological functions in multiple organ systems, are essential...
9.
Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al.
Leukemia
. 2020 Jan;
34(7):1972.
PMID: 31949266
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al.
Leukemia
. 2019 Oct;
33(11):2628-2639.
PMID: 31576004
To date, only one subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL) can be effectively treated by differentiation therapy utilizing all-trans retinoic acid (ATRA). Non-APL AMLs are resistant...